RedHill Biopharma announces positive results of COVID-19 opaganib study

By Nikita Chaurasia  | Date: 2021-01-05

RedHill Biopharma announces positive results of COVID-19 opaganib study

Israeli specialty biopharmaceutical company, RedHill Biopharma Ltd., has announced the preliminary data from the phase-2 clinical trials of its drug opaganib which was administered orally in patients suffering from COVID-19. The trial round included around 40 participants, with the study showing positive signals of efficacy and safety.

For the uninitiated, opaganib is an oral drug that acts as a sphingosine kinase-2 (SK2) inhibitor and is used for treating individuals with COVID-19 pneumonia. Its primary function is to target the host cell responsible for viral replication, thereby potentially minimizing the likelihood of viral resistance.

It is also worth mentioning that RedHill’s opaganib has received orphan drug designation by the U.S. Food & Drug Administration (FDA) for treating cholangiocarcinoma. The drug is currently being evaluated in a phase-2 study for the treatment of prostate cancer as well as cholangiocarcinoma.

If reports are to be believed, the preliminary data comes from a randomized, placebo-controlled, double-blind clinical trial round conducted on COVID-19 patients that required oxygen support. Furthermore, the trials found that there were no material safety differences between opaganib and the placebo treatment arms.

The drug reportedly demonstrated consistent progressive improvement in reducing oxygen requirements of the patients by the 14th day of the trial. Specifically, 52.6% of the patients in the opaganib group no longer required oxygen support as compared to 22.2% in the placebo group.

Medical director of RedHill Biopharma, Mark L. Levitt, was quoted saying that the organization expects the preliminary results from the recently conducted COVID-19 therapy study to support its global phase 2/3 study. The company will compile a robust data set for supporting the potential filing of emergency use applications, he added.

About RedHill Biopharma Ltd.

Since its inception in 2009, Redhill Biopharma primarily focuses on the treatment of gastrointestinal and other infectious diseases. The company’s products are based on several technology platforms and are known to be more affordable than other chemical entities under development.

Source credits –

https://www.prnewswire.com/news-releases/redhill-biopharma-annonce-les-resultats-positifs-de-la-phase-2-de-l-etude-covid-19-sur-l-opaganib-en-termes-de-securite-et-d-efficacite-845306278.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...